The fund’s investment thesis is built on a clear focus: supporting innovative companies with low scientific or technological risk that are close to commercialization. Key sectors include biotechnology, precision medicine, advanced diagnostics, digital therapies, artificial intelligence, and big data applied to healthcare. These choices address the growing needs tied to an aging population, chronic diseases, and personalized treatments, while striving to generate measurable economic and societal impact.
The fund plans to invest in 10 to 12 companies, primarily in Spain, with individual tickets of up to €15 million. Its strategy stands out for its emphasis on startups in pre-commercial stages, where access to capital and strategic expertise is crucial to accelerate market entry.
SYNGOI, a company specializing in synthetic DNA for advanced therapies, represents the fund’s first operation. Based in Zamudio, Bizkaia, it will use this investment to expand its production capacity and support over 25 concurrent client projects.
The fund’s financing structure relies on several strategic partners. The Centre for Technological Development and Innovation (CDTI) has committed up to €58 million through its Innvierte Program, designed to promote innovative therapies and drug development. BUENAVISTA EQUITY PARTNERS, managing over €1 billion across various investment vehicles, and COLUMBUS VENTURE PARTNERS, a biotech specialist with €400 million under management, bring complementary expertise and resources. The fund plans to finalize its fundraising with institutional and private investors to reach its hard cap.
